Drugs with known pharmacological profiles, such as monensin, disulfiram and salinomycin, show cancer-selective inhibition of prostate cancer cell growth by increasing oxidative stress

Kirsi Ketola; Paula Vainio; Pasi Halonen; Pekka Kohonen; Vidal Fey; Roland Grafström; Merja Perälä; Olli Kallioniemi; Kristiina Iljin

doi:10.1016/S1359-6349(10)71041-7

Drugs with known pharmacological profiles, such as monensin, disulfiram and salinomycin, show cancer-selective inhibition of prostate cancer cell growth by increasing oxidative stress

Kirsi Ketola
, Paula Vainio
, Pasi Halonen
, Pekka Kohonen
, Vidal Fey
, Roland Grafström
, Merja Perälä
, Olli Kallioniemi
, Kristiina Iljin

University of Turku
VTT (former employee or external)
Institute for Molecular Medicine Finland (FIMM)

Research output: Contribution to journal › Other journal contribution › Scientific › peer-review

Original language	English
Article number	234
Pages (from-to)	61-62
Journal	European Journal of Cancer: Supplement
Volume	8
Issue number	5
DOIs	https://doi.org/10.1016/S1359-6349(10)71041-7
Publication status	Published - 2010
MoE publication type	Not Eligible
Event	21st Meeting of the European Association for Cancer Research, EACR-21 - Oslo, Norway Duration: 26 Jun 2010 → 29 Jun 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/S1359-6349(10)71041-7

Cite this

Ketola, K., Vainio, P., Halonen, P., Kohonen, P., Fey, V., Grafström, R., Perälä, M., Kallioniemi, O., & Iljin, K. (2010). Drugs with known pharmacological profiles, such as monensin, disulfiram and salinomycin, show cancer-selective inhibition of prostate cancer cell growth by increasing oxidative stress. European Journal of Cancer: Supplement, 8(5), 61-62. Article 234. https://doi.org/10.1016/S1359-6349(10)71041-7

@article{bf5119b108fd4b40895684e2ae29e928,

title = "Drugs with known pharmacological profiles, such as monensin, disulfiram and salinomycin, show cancer-selective inhibition of prostate cancer cell growth by increasing oxidative stress",

author = "Kirsi Ketola and Paula Vainio and Pasi Halonen and Pekka Kohonen and Vidal Fey and Roland Grafstr{\"o}m and Merja Per{\"a}l{\"a} and Olli Kallioniemi and Kristiina Iljin",

note = "Poster abstract; 21st Meeting of the European Association for Cancer Research, EACR-21, EACR-21 ; Conference date: 26-06-2010 Through 29-06-2010",

year = "2010",

doi = "10.1016/S1359-6349(10)71041-7",

language = "English",

volume = "8",

pages = "61--62",

journal = "European Journal of Cancer: Supplement",

issn = "1359-6349",

publisher = "Elsevier",

number = "5",

}

Ketola, K, Vainio, P, Halonen, P, Kohonen, P, Fey, V, Grafström, R, Perälä, M, Kallioniemi, O & Iljin, K 2010, 'Drugs with known pharmacological profiles, such as monensin, disulfiram and salinomycin, show cancer-selective inhibition of prostate cancer cell growth by increasing oxidative stress', European Journal of Cancer: Supplement, vol. 8, no. 5, 234, pp. 61-62. https://doi.org/10.1016/S1359-6349(10)71041-7

Drugs with known pharmacological profiles, such as monensin, disulfiram and salinomycin, show cancer-selective inhibition of prostate cancer cell growth by increasing oxidative stress. / Ketola, Kirsi; Vainio, Paula; Halonen, Pasi et al.
In: European Journal of Cancer: Supplement, Vol. 8, No. 5, 234, 2010, p. 61-62.

Research output: Contribution to journal › Other journal contribution › Scientific › peer-review

TY - JOUR

T1 - Drugs with known pharmacological profiles, such as monensin, disulfiram and salinomycin, show cancer-selective inhibition of prostate cancer cell growth by increasing oxidative stress

AU - Ketola, Kirsi

AU - Vainio, Paula

AU - Halonen, Pasi

AU - Kohonen, Pekka

AU - Fey, Vidal

AU - Grafström, Roland

AU - Perälä, Merja

AU - Kallioniemi, Olli

AU - Iljin, Kristiina

N1 - Poster abstract

PY - 2010

Y1 - 2010

U2 - 10.1016/S1359-6349(10)71041-7

DO - 10.1016/S1359-6349(10)71041-7

M3 - Other journal contribution

SN - 1359-6349

VL - 8

SP - 61

EP - 62

JO - European Journal of Cancer: Supplement

JF - European Journal of Cancer: Supplement

IS - 5

M1 - 234

T2 - 21st Meeting of the European Association for Cancer Research, EACR-21

Y2 - 26 June 2010 through 29 June 2010

ER -